Polish biotechnology company Selvita, announced today the appointment of Mr. Piotr Prelich to the position of Vice President of Sales and Marketing. Mr. Prelich will be responsible for the further establishment of Selvita's brand in the pharmaceutical preclinical outsourcing market, both in Poland and abroad, as well as for the sales of services offered by Selvita and its subsidiary BioCentrum.

Mr. Piotr Prelich worked from 2007 to 2010 at Invitrogen (Life Technologies group) in the United Kingdom, as Director of Sales and Marketing of the HLA product line (transplantation and diagnostics), for the EMEA region. His previous professional experience includes sales positions in pharmaceutical companies such as Sanofi-Winthrop, Chinoin, Novo Nordisk, Roche Diagnostics and Abbott in Poland and Austria. In 1999-2007 he served as the CEO of Hark Company, specializing in laboratory equipment. He graduated from the Faculty of Medicine, from the Medical University of Lodz.

"Piotr's appointment constitutes for us the commencement of the next phase of Selvita's expansion in the European market," said Pawel Przewiezlikowski, Selvita's CEO. "Piotr has extensive contacts in the pharmaceutical and diagnostic industry, experience in building European sales structures in global biotechnology companies, as well as the skills required to manage large outsourcing projects. Strengthening of Selvita Group's management team by Piotr will enable us to deepen the relationships with large clients from the global pharmaceutical industry."

"Selvita, probably the largest independent biotechnology research and development company from all new member countries of the European Union, is a valuable partner for domestic and foreign pharmaceutical companies, who want to quickly and cost-effectively introduce innovative drugs to the market," said Piotr Prelich. "My goal at Selvita is to help the company join the group of the world's largest research outsourcing companies over the next few years."

About Selvita - www.selvita.com
Selvita Group is a product and solution provider for the pharmaceutical and biotechnology industry from Krakow, Poland. The company was established in 2007, and ever since its mission has been to serve the clients with a comprehensive panel of products and solutions targeted at lowering the cost of, and accelerating, the introduction of new drugs to the market.

Selvita Group employs a highly specialized team of 120 professionals in various fields of life sciences, 40% of them with a PhD degree. We also enjoy a very good cooperation with numerous leading research institutes and universities from Poland as well as Europe and USA.

Since 2010, Selvita is also owner of BioCentrum, which provides in-vitro preclinical ADMET services, biochemistry services with special focus on protein engineering and antibody development.  

Selvita Group has experience in several areas of life sciences, and offers the following types of projects:

• Integrated drug discovery projects which include in silico modeling, and synthesis of a target-focused library, lead-optimization and preclinical development.
• chemistry services, including medicinal chemistry, contract synthesis, synthesis pathway design and optimization, analytical chemistry, as well as computational chemistry services.  
• biology services, including assay development such as ELISA and cytotoxicity assays, spectrophotometric, fluorescence and fluorescence anisotrophy measurements, as well as cell cycle arrest analysis and apoptosis/necrosis identification